G. Davis

Two Distinct Patterns of Clostridium difficile Diversity Across Europe Indicating Contrasting Routes of Spread

M. Delmée, E. Kuijper, T. Peto, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut model.

M. Wilcox, A. Buckley, E. Clark, 2020, The Journal of antimicrobial chemotherapy.

The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infection

M. Wilcox, A. Buckley, E. Clark, 2021, The Journal of antimicrobial chemotherapy.

Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID)

J. Lawrence, B. Gärtner, M. Wilcox, 2020, Frontiers in Public Health.

Factors affecting reported Clostridioides difficile infection rates; the more you look the more you find, but should you believe what you see?

B. Gärtner, M. Wilcox, E. Bouza, 2020, Anaerobe.

Variability in testing policies and impact on reported Clostridium difficile infection rates: results from the pilot Longitudinal European Clostridium difficile Infection Diagnosis surveillance study (LuCID)

M. Wilcox, N. Petrosillo, C. Eckert, 2016, European Journal of Clinical Microbiology & Infectious Diseases.

A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018

E. Kuijper, F. Allantaz, M. Wilcox, 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Underdiagnosis of Clostridium diffi cile across Europe

M. Delmée, M. Wilcox, E. Bouza, 2014 .

Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).

M. Wilcox, M. Vehreschild, J. Vehreschild, 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID).

M. Delmée, E. Kuijper, M. Wilcox, 2014, The Lancet. Infectious diseases.

Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013.

M. Wilcox, K. Davies, H. Ashwin, 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Trehalose-Induced Remodelling of the Human Microbiota Affects Clostridioides difficile Infection Outcome in an In Vitro Colonic Model: A Pilot Study

M. Wilcox, T. Higashiyama, S. Mitra, 2021, Frontiers in Cellular and Infection Microbiology.

Pilot study: Trehalose-induced remodelling of the human microbiota affects Clostridioides difficile infection outcome in an in vitro colonic model

M. Wilcox, T. Higashiyama, S. Mitra, 2021, bioRxiv.

Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection

M. Henn, M. Wilcox, H. Harris, 2021, NPJ biofilms and microbiomes.